Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $36.20.

Several research analysts have issued reports on the company. Scotiabank dropped their target price on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. JPMorgan Chase & Co. raised their price objective on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, November 21st. UBS Group began coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 price objective on the stock. The Goldman Sachs Group raised their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com downgraded Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ:SNDX opened at $15.99 on Friday. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -4.40 and a beta of 0.90. The stock’s 50-day simple moving average is $13.92 and its two-hundred day simple moving average is $17.00. Syndax Pharmaceuticals has a 52-week low of $12.06 and a 52-week high of $25.34.

Insider Activity at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 3,777 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $58,543.50. Following the sale, the chief financial officer now owns 90,746 shares of the company’s stock, valued at $1,406,563. The trade was a 4.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Neil Gallagher sold 4,618 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is owned by company insiders.

Institutional Trading of Syndax Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Syndax Pharmaceuticals in the 4th quarter worth approximately $26,000. Values First Advisors Inc. bought a new stake in Syndax Pharmaceuticals in the 3rd quarter worth approximately $30,000. Quantbot Technologies LP purchased a new position in shares of Syndax Pharmaceuticals in the 3rd quarter worth approximately $49,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the period. Finally, Virtus ETF Advisers LLC boosted its holdings in shares of Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock worth $70,000 after purchasing an additional 827 shares during the period.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).